tocilizumab biosimilar (Yinkang Biopharma)

N/A

Report date: 2025/03/20 10:08:59

Base Information

Drug Nametocilizumab biosimilar (Yinkang Biopharma)
Drug Alias NameYinkang-006
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIL-6 receptor antagonists
TargetsIL-6 receptor
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYinkang Biopharma Inc.
China Registration ClassN/A

Develop Information

Active CompaniesYinkang Biopharma Inc.
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A